(CIDRAP News) – At an Infectious Diseases Society of America (IDSA) symposium in Washington, DC, today on seasonal and pandemic influenza, a group of experts fielded questions from reporters on some of the new trends and emerging issues, including prepandemic strategies for H5N1 avian influenza vaccines, now that some countries are stockpiling them.
(CIDRAP News) New human cases of H5N1 avian influenza were reported in Cambodia and Egypt today, while Indonesian officials, according to one news service, said they would not resume sharing H5N1 virus samples unless vaccine manufacturers promise to provide the country with free pandemic flu vaccines.
(CIDRAP News) – Low doses of a cell-based avian flu vaccine triggered a good immune response to the H5N1 avian influenza virus, according to preliminary results of a clinical trial by Baxter International of Deerfield, Ill., maker of the vaccine.
(CIDRAP News) An H5N1 avian influenza vaccine made by GlaxoSmithKline (GSK) triggered a good immune response in human volunteers at a much lower dose than other H5N1 vaccines reported so far, which means that hundreds of millions of doses could be produced by next year, the company announced today.
(CIDRAP news) In a human trial in France, an experimental H5N1 avian influenza vaccine with an adjuvant showed modestly better performance at a lower dose compared with a similar H5N1 vaccine that was tested earlier in the United States.
(CIDRAP News) – The World Health Organization (WHO) is preparing to recommend that governments consider stockpiling vaccines against the H5N1 avian influenza virus now, rather than waiting until a human flu pandemic emerges, according to a story published online today by New Scientist magazine.
(CIDRAP News) The World Health Organization (WHO) said today it is launching an effort to quickly develop a vaccine against influenza A(H5N1), the avian flu virus that has caused at least five human deaths in Vietnam.